Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Hemostemix Inc
V.HEM
Alternate Symbol(s):
HMTXF
Healthcare
Biotechnology
Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP...
-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSXV:HEM)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(67)
•••
Jon9800
X
View Profile
View Bullboard History
Post by
Jon9800
on Jul 01, 2022 7:34am
$HMTXF common share and warrant elaboration
The recently announced private placement of 15 million units has put the entire OTC in awe, in which each full unit consists of one common share and one purchase warrant, each full warrant entitles
...more
(67)
•••
Jon9800
X
View Profile
View Bullboard History
Post by
Jon9800
on Jul 01, 2022 7:19am
Potential capability of NCP-01 by Hemostemix
Neuropathic pain syndromes can be treated with NCP-01 and its autologous stem cell technology, which can treat disorders of the central and peripheral nervous systems. Spinal cord injury, chronic
...more
Discover Options Trading Strategies to Minimize your Tax Burden
posted Dec 01, 2024 9:00am by
Bank of Montreal
-
|
Options trading doesn’t come without tax implications, but there are ways investors can still optimize their after-tax returns with just a little bit of understanding. Approaches for investors to keep in mind are holding periods, wash-sales rule, tax advantaged accounts, and qualified cover calls. BMO’s enhanced InvestorLine platform. Industry-leading tools and capabilities specifically designed to empower options traders. ...read more
(2)
•••
ashokswain861
X
View Profile
View Bullboard History
Comment by
ashokswain861
on Jun 30, 2022 3:50pm
RE:$HEM 52 Weeks Range
This is a billion $$ co trading for pennies, I am buying all day long
(6)
•••
Tradeconnects
X
View Profile
View Bullboard History
Post by
Tradeconnects
on Jun 30, 2022 3:45pm
$HEM 52 Weeks Range
$HEM has recorded a high range of price in the last 52 weeks. It is $0.1300-$0.4200.
(67)
•••
Jon9800
X
View Profile
View Bullboard History
Post by
Jon9800
on Jun 30, 2022 3:25pm
$IBOGF announced a crucial addition of clinical trials direc
Julie Dumouchel has been named Director of Clinical Trials at UI, which is a significant strategic move. Julie Dumouchel has 25 years of experience in the pharmaceutical sector, where she has worked
...more
(67)
•••
Jon9800
X
View Profile
View Bullboard History
Post by
Jon9800
on Jun 30, 2022 3:19pm
$IBOGF CO-founder to present his findings at a global summit
The company recently announced that DR Alberto Sola, CO-Founder Universal Ibogaine will be presenting his recent findings on the title Ibogaine Hydrochloride and Acute Opioid Detox.
(13)
•••
trade007
X
View Profile
View Bullboard History
Post by
trade007
on Jun 30, 2022 2:03pm
$HMTXF announced incorporation of an entirely owned
The business is happy to announce that PreCerv Inc. ("PreCerv") has been incorporated as a completely owned subsidiary. A worldwide field of use licence for NCP-01 and its autologous stem
...more
(67)
•••
Jon9800
X
View Profile
View Bullboard History
Post by
Jon9800
on Jun 30, 2022 8:17am
$HEM perfect patent record and universal acknowledgement
$HEM owns a total of 91 patents in 5 different categories falling under 25 jurisdictions and also been a recipient of world economic forum technology award.
(67)
•••
Jon9800
X
View Profile
View Bullboard History
Post by
Jon9800
on Jun 30, 2022 7:56am
CEO Hemostemix highlighted the mounting demand of $HEM.
Thomas Smeenk on the latest update stated “for the stem cell space it is the right time to take a bite of the apple” Thomas later said the management board have invested about $4.5 Million in the
...more
(67)
•••
Jon9800
X
View Profile
View Bullboard History
Post by
Jon9800
on Jun 30, 2022 7:31am
Efficacy of NCP-01 a futuristic product by Hemostemix
Neuropathic pain syndromes can be treated with NCP-01 and its autologous stem cell technology, which can treat disorders of the central and peripheral nervous systems. Spinal cord injury, chronic
...more
(13)
•••
trade007
X
View Profile
View Bullboard History
Post by
trade007
on Jun 30, 2022 7:24am
$HMTXF Average Volume Rate
Hemostemix Inc. is seen to be doing well in the OTC market with its ticker symbol $HMTXF. The average volume in the last 30 days is recorded to be above $21K.
(67)
•••
Jon9800
X
View Profile
View Bullboard History
Post by
Jon9800
on Jun 29, 2022 2:51pm
$HMTXF average volume expenditure analysis
$HMTXF offers a sum of approx 22,798 for daily trade and investor related activities on the OTC market which is likely to vary as per the market’s demeanor.
(6)
•••
Tradeconnects
X
View Profile
View Bullboard History
Post by
Tradeconnects
on Jun 29, 2022 2:46pm
$HEM multiplying with consummate elegance
$HEM has been on quite an impressive venture, the stock has been seen to have ground breaking potential by the investors and is a worthy investment per se, shares are trading at $0.255 with a major
...more
(67)
•••
Jon9800
X
View Profile
View Bullboard History
Post by
Jon9800
on Jun 29, 2022 2:34pm
regains lawful possession of all its missing intellectual pr
All the intellectual data including all phase 2 clinical trial data, all the historical data from hemostemix Israel, and the randomized table required to analyze North-American and South-African ACP
...more
(17)
•••
christiano
X
View Profile
View Bullboard History
Post by
christiano
on Jun 29, 2022 2:15pm
$HMTXF Upper and Lower Price in the Last 52 weeks
Hemostemix Inc. holds a significant position over the OTC market with its greater difference between the lower and higher ranges of trading, which is $0.0991-$0.3279 in the last 52 weeks.
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >